Compare
Camp4 Therapeutics Corp vs TherapeuticsMD, Inc. vs China Pharma Holdings, Inc. vs Upstream Bio, Inc.
| Latest fiscal year | Camp4 Therapeutics Corp CAMP | TherapeuticsMD, Inc. TXMD | China Pharma Holdings, Inc. CPHI | Upstream Bio, Inc. UPB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $3.50M | $3.02M | $4.14M | $2.85M |
| Revenue growth (YoY) | +436.5% | +71.6% | -8.5% | +20.4% |
| Gross margin | n/a | n/a | -3.2% | n/a |
| Operating margin | n/m | -145.3% | -78.2% | n/m |
| Net margin | n/m | -18.8% | -76.9% | n/m |
| Net income | -$80.40M | -$569.0K | -$3.19M | -$143.44M |
| EPS (Diluted) | -$2.65 | -$0.05 | -$0.74 | -$2.66 |
| Operating cash flow | -$29.55M | $2.45M | $148.3K | -$133.28M |
| Free cash flow | -$29.83M | n/a | $88.9K | -$133.44M |
| Cash & equivalents | $109.52M | n/a | $345.1K | $101.58M |
| Total assets | $117.81M | $37.66M | $31.00M | $353.77M |
| Total liabilities | $70.10M | $10.78M | $8.26M | $14.00M |
| Shareholders' equity | $47.70M | $26.88M | $22.74M | $339.77M |
| Return on year-end equity | -168.5% | -2.1% | -14.0% | -42.2% |
| Shares outstanding | 51.90M | 11.57M | 15.52M | 54.24M |
Revenue, most recent five fiscal years
| Fiscal year | Camp4 Therapeutics Corp | TherapeuticsMD, Inc. | China Pharma Holdings, Inc. | Upstream Bio, Inc. |
|---|---|---|---|---|
| Latest | $3.50M Ended 2025-12-31 | $3.02M Ended 2025-12-31 | $4.14M Ended 2025-12-31 | $2.85M Ended 2025-12-31 |
| 1 year earlier | $652.0K Ended 2024-12-31 | $1.76M Ended 2024-12-31 | $4.53M Ended 2024-12-31 | $2.37M Ended 2024-12-31 |
| 2 years earlier | $350.0K Ended 2023-12-31 | $1.30M Ended 2023-12-31 | $7.01M Ended 2023-12-31 | $2.38M Ended 2023-12-31 |
| 3 years earlier | n/a | $69.96M Ended 2022-12-31 | $8.10M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $2.57M Ended 2021-12-31 | $9.64M Ended 2021-12-31 | n/a |